(NASDAQ: TGTX) Tg Therapeutics's forecast annual revenue growth rate of 32.99% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.9%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.78%.
Tg Therapeutics's revenue in 2026 is $700,349,000.On average, 9 Wall Street analysts forecast TGTX's revenue for 2026 to be $147,146,998,768, with the lowest TGTX revenue forecast at $138,470,221,453, and the highest TGTX revenue forecast at $155,073,666,540. On average, 9 Wall Street analysts forecast TGTX's revenue for 2027 to be $198,702,486,840, with the lowest TGTX revenue forecast at $182,016,376,620, and the highest TGTX revenue forecast at $221,511,940,260.
In 2028, TGTX is forecast to generate $252,740,990,580 in revenue, with the lowest revenue forecast at $220,593,438,780 and the highest revenue forecast at $294,838,975,080.